The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

Background Limited information is available regarding the risk of incident liver disease in patients with psoriasis receiving systemic therapies. Objectives To describe the liver safety findings of conventional and modern systemic therapies for moderate-to-severe psoriasis, and to compare the relati...

Full description

Bibliographic Details
Main Authors: Mónica Munera-Campos, Jaime Vilar-Alejo, Raquel Rivera, Jose-Manuel Carrascosa, Esteban Daudén, Enrique Herrera-Acosta, Antonio Sahuquillo-Torralba, Francisco J. Gómez-García, Ofelia Baniandrés-Rodríguez, Pablo de la Cueva, Jose-Luis López-Estebaranz, Isabel Belinchón, Marta Ferran, Jose Riera-Monroig, Lourdes Rodriguez, Gregorio Carretero, Carmen García-Donoso, Ferran Ballescá, Mar Llamas-Velasco, Enrique Herrera-Ceballos, Conrad Pujol-Marco, Lula María Nieto-Benito, Diana P. Ruiz-Genao, Mercè Alsina, Miguel A. Descalzo, Ignacio García-Doval, the BIOBADADERM Study Group
Format: Article
Language:English
Published: Taylor & Francis Group 2022-05-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
risk
psoriasis treatment
liver
hepatic
adverse event
Online Access:http://dx.doi.org/10.1080/09546634.2021.1922572

Internet

http://dx.doi.org/10.1080/09546634.2021.1922572

Similar Items